Baidu
map

Int J Cardiol: 糖尿病增加心衰无房颤患者缺血性卒中发生的风险

2016-04-10 MedSci MedSci原创

背景:糖尿病心衰患者发生缺血性卒中、全身性栓塞及全因死亡率的风险研究较少。研究者旨在评估糖尿病患者,无房颤的心衰患者发生这些终点的风险。方法:丹麦研究者进行了一项人群为基础的全国性队列研究,从丹麦全国登记记录中选取2000-2012年间,诊断为心衰的非抗凝治疗的患者。研究者计算39357名心衰患者(其中18.1%为糖尿病患者)中,1年后 RR值评估糖尿病和事件发生风险相关性的。分析考虑死亡的竞争风

背景:糖尿病心衰患者发生缺血性卒中、全身性栓塞及全因死亡率的风险研究较少。研究者旨在评估糖尿病患者,无房颤的心衰患者发生这些终点的风险。

方法:丹麦研究者进行了一项人群为基础的全国性队列研究,从丹麦全国登记记录中选取2000-2012年间,诊断为心衰的非抗凝治疗的患者。研究者计算39357名心衰患者(其中18.1%为糖尿病患者)中,1年后 RR值评估糖尿病和事件发生风险相关性的。分析考虑死亡的竞争风险。

结果:随访1年后,与非糖尿病患者相比,糖尿病患者发生所有终点的绝对风险增加(缺血性卒中:4.1% vs 2.8%;全身性栓塞:11.9 % vs 8.6%;全因死亡:22.1 % vs 21.4%)。糖尿病与缺血性卒中(aRR:1.27,95% CI:1.07-1.51);全身性栓塞(RR:1.20,95% CI:1.11-1.30);和全因死亡率(RR 1.17,95% CI:1.11-1.23)风险增加相关。另外,糖尿病诊断的时间与缺血性卒中、全身性栓塞,和全因死亡校正累积发生率增高相关。

结论:无房颤的心衰患者中,即使校正合并其他心血管危险因素,与非糖尿病患者相比,糖尿病患者与缺血性脑卒中,全身性血栓栓塞,和全因死亡的风险显著升高相关。需要重点加强糖尿病患者心衰的二级预防。

原文出处:

Melgaard L, Gorst-Rasmussen A, et al. Diabetes mellitus and risk of ischemic stroke in patients with heart failure and no atrial fibrillation. Int J Cardiol. 2016 Apr 15.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1781702, encodeId=79b41e8170287, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jan 27 15:05:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892737, encodeId=9ce71892e3737, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 18 14:05:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806073, encodeId=08d318060e37f, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Feb 10 17:05:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78103, encodeId=760de810385, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78104, encodeId=36d0e81044e, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614294, encodeId=8f67161429469, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Tue Apr 12 00:05:00 CST 2016, time=2016-04-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1781702, encodeId=79b41e8170287, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jan 27 15:05:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892737, encodeId=9ce71892e3737, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 18 14:05:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806073, encodeId=08d318060e37f, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Feb 10 17:05:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78103, encodeId=760de810385, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78104, encodeId=36d0e81044e, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614294, encodeId=8f67161429469, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Tue Apr 12 00:05:00 CST 2016, time=2016-04-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1781702, encodeId=79b41e8170287, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jan 27 15:05:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892737, encodeId=9ce71892e3737, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 18 14:05:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806073, encodeId=08d318060e37f, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Feb 10 17:05:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78103, encodeId=760de810385, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78104, encodeId=36d0e81044e, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614294, encodeId=8f67161429469, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Tue Apr 12 00:05:00 CST 2016, time=2016-04-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1781702, encodeId=79b41e8170287, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jan 27 15:05:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892737, encodeId=9ce71892e3737, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 18 14:05:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806073, encodeId=08d318060e37f, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Feb 10 17:05:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78103, encodeId=760de810385, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78104, encodeId=36d0e81044e, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614294, encodeId=8f67161429469, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Tue Apr 12 00:05:00 CST 2016, time=2016-04-12, status=1, ipAttribution=)]
    2016-04-14 李继凯

    文章不错

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1781702, encodeId=79b41e8170287, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jan 27 15:05:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892737, encodeId=9ce71892e3737, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 18 14:05:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806073, encodeId=08d318060e37f, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Feb 10 17:05:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78103, encodeId=760de810385, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78104, encodeId=36d0e81044e, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614294, encodeId=8f67161429469, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Tue Apr 12 00:05:00 CST 2016, time=2016-04-12, status=1, ipAttribution=)]
    2016-04-14 李继凯

    值得学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1781702, encodeId=79b41e8170287, content=<a href='/topic/show?id=5db8409ed8' target=_blank style='color:#2F92EE;'>#Cardiol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4097, encryptionId=5db8409ed8, topicName=Cardiol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Fri Jan 27 15:05:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1892737, encodeId=9ce71892e3737, content=<a href='/topic/show?id=c738e93521f' target=_blank style='color:#2F92EE;'>#缺血性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79352, encryptionId=c738e93521f, topicName=缺血性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sat Mar 18 14:05:00 CST 2017, time=2017-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1806073, encodeId=08d318060e37f, content=<a href='/topic/show?id=b649e9358fa' target=_blank style='color:#2F92EE;'>#缺血性卒#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79358, encryptionId=b649e9358fa, topicName=缺血性卒)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Fri Feb 10 17:05:00 CST 2017, time=2017-02-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78103, encodeId=760de810385, content=文章不错, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=78104, encodeId=36d0e81044e, content=值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=174, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Thu Apr 14 18:30:00 CST 2016, time=2016-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1614294, encodeId=8f67161429469, content=<a href='/topic/show?id=64f95426122' target=_blank style='color:#2F92EE;'>#房颤患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54261, encryptionId=64f95426122, topicName=房颤患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=937e19519012, createdName=hittouch, createdTime=Tue Apr 12 00:05:00 CST 2016, time=2016-04-12, status=1, ipAttribution=)]

相关资讯

ENDO 2016:甲状腺功能减退可能增加糖尿病风险

内分泌学会年会上称,即使是轻度甲状腺功能减退,也会增加2型糖尿病风险。荷兰鹿特丹港市伊拉斯莫斯医学中心的Layal Chaker博士说:“甲状腺功能低于下限或是在正常范围下限,都会增加2型糖尿病风险,或是加速前驱糖尿病发展为2型糖尿病的进展。”她说:“前驱糖尿病患者发展为糖尿病的风险在正常甲功上限时为19%,而下限时则为35%。”这项基于人群的前瞻性队列研究,Chaker和同事对8452名≥45岁

今年世界卫生日的主题是糖尿病

背景2008年全球估计约有3.47亿人患有糖尿病。目前流行率仍呈上升趋势,尤其在低收入和中等收入国家。2012年总共约有150万人直接死于这一疾病,其中80%以上的死亡病例发生在低收入和中等收入国家。据世卫组织预测,到2030年,糖尿病将成为第七项主要死亡原因。糖尿病是一种慢性病,当胰腺产生不了足够的胰岛素或者人体无法有效利用所产生的胰岛素时,就会发生糖尿病。胰岛素是一种调节血糖的荷尔蒙,能够给予

世卫:中国成年人近10%患糖尿病

4月7日是世界卫生日,今年的主题为“应对糖尿病”。世卫组织于6日首次发布全球糖尿病报告,显示全球糖尿病成年人患者近40年内增加了3倍,其中多数生活在发展中国家。报告显示,中国成年人患糖尿病率接近10%。 发展中国家糖尿病最严重 根据这份报告,全球18岁以上人群中,1980年糖尿病患者为1.08亿人,2014年增加至4.22亿人,占全球总人口的8.5%。 报告说,没有任何

Lancet:自1980年以来全球糖尿病的人数增加了4倍之多

非传染性疾病的其中一个全球目标是到2025停止年龄标准化成人糖尿病患病率的增长维持在2010年的水平。本研究旨在评估全球糖尿病的发展趋势,各国如何才能实现上述的全球目标,确定糖尿病患病率的变化,以及人口的增长和老龄化,影响着成人糖尿病患者的数量。

Circulation:糖尿病患者冠状动脉支架术后心肌梗死的预防

背景:冠状动脉支架术后,糖尿病(DM)患者复发性脑缺血事件发生的风险很高。研究者评估参与双联抗血小板治疗研究(DAPT)中糖尿病患者持续应用噻吩并吡啶的影响。方法:冠状动脉内支架植入术后,噻吩吡啶类药物加阿司匹林治疗12个月。11648例非缺血性或出血事件的患者,根据用药随机分为持续的噻吩吡啶类药物联合阿司匹林或安慰剂联合阿司匹林。结果:与非糖尿病患者(8257例)相比,糖尿病患者(3391例)死

Diabetologia:1型糖尿病增加癫痫发病风险

1型糖尿病显然已成为全球性的重大公共卫生问题,1型糖尿病可能会伴随潜在的神经并发症。有研究表明1型糖尿病与癫痫之间存在相关性,但并没有进行更多的相关研究,本研究旨在评估在中国台湾1型糖尿病和癫痫之间的关系。研究人员收纳了来自台湾全民健康保险研究数据库(NHIRD)2568名1型糖尿病患者的数据,并进行了回顾性队列分析。与对照组相比,在1型糖尿病患者中患癫痫的风险明显高于对照组(p < 0.0

Baidu
map
Baidu
map
Baidu
map